Trial reportScientific reports2014
Comparative effectiveness of Di'ao Xin Xue Kang capsule and Compound Danshen tablet in patients with symptomatic chronic stable angina.
Trial report in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Trial
- Danhong injection in the treatment of chronic stable angina: study protocol for a randomized controlled trial.Trials · 2015Trial
- Influencing factors, evolution, and strategies for improving the quality of traditional Chinese medicine patents: an empirical study based on patent invalidation cases.Annals of medicine · 2024Article
- Safety of combined drug use in patients with cardiovascular and cerebrovascular diseases: an analysis based on the spontaneous reporting database of adverse drug reactions in Hubei Province.Frontiers in pharmacology · 2024Article
- Discovery of Drug-Responsive Phenomic Alteration-Related Driver Genes in the Treatment of Coronary Heart Disease.Pharmacogenomics and personalized medicine · 2023Article
- Diosgenin and Its Analogs: Potential Protective Agents Against Atherosclerosis.Drug design, development and therapy · 2022Review
- Effect of Traditional Chinese Medicine on the Cardiovascular Diseases.Frontiers in pharmacology · 2022Review
- Advances in steroidal saponins biosynthesis.Planta · 2021Review
- Standard Operating Procedures for Chinese Medicine Data Monitoring Committees of Clinical Studies.Chinese journal of integrative medicine · 2021Article
- Exploring the Biological Mechanism of Huang Yam in Treating Tumors and Preventing Antitumor Drug-Induced Cardiotoxicity Using Network Pharmacology and Molecular Docking Technology.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Molecular Cloning and Functional Characterization of a Sterol 3-Frontiers in plant science · 2021Article
- The Clinical Efficacy of Phytochemical Medicines Containing Tanshinol and Ligustrazine in the Treatment of Stable Angina: A Systematic Review and Meta-Analysis.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Article
- Inhibitory effects of isocryptotanshinone on gastric cancer.Scientific reports · 2018Article
- Di'ao Xinxuekang Capsule, a Chinese Medicinal Product, Decreases Serum Lipids Levels in High-Fat Diet-Fed ApoEFrontiers in pharmacology · 2018Article
- Acute and long-term cardioprotective effects of the Traditional Chinese Medicine MLC901 against myocardial ischemia-reperfusion injury in mice.Scientific reports · 2017Article
- Extract of Sheng-Mai-San Ameliorates Myocardial Ischemia-Induced Heart Failure by Modulating CaInternational journal of molecular sciences · 2017Article
- Dioscin induces prostate cancer cell apoptosis through activation of estrogen receptor-β.Cell death & disease · 2017Article
- Potent effects of dioscin against pancreatic cancer via miR-149-3P-mediated inhibition of the Akt1 signalling pathway.British journal of pharmacology · 2017Article
- A Review of Chinese Herbal Medicine for the Treatment of Chronic Heart Failure.Current pharmaceutical design · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A high proportion of patients with stable angina remains symptomatic despite multiple treatment options. Di'ao Xinxuekang (XXK) capsule and Compound Danshen (CDS) tablet have been approved for treating angina pectoris for more than 20 years in China. We compare the anti-anginal effectiveness of XXK capsule and CDS tablet in patients with symptomatic chronic stable angina. A randomized, multicenter, double-blind, parallel-group, superiority trial was conducted in 4 study sites. 733 patients with symptomatic chronic stable angina were included in the full analysis set. The primary outcomes were the proportion of patients who were angina-free and the proportion of patients with normal electrocardiogram (ECG) recordings during 20 weeks treatment. Compared with CDS, XXK significantly increased the proportion of angina-free patients, but no significant difference was noted in the proportion of patients with normal ECG recordings. Weekly angina frequency and nitroglycerin use were significantly reduced with XXK versus CDS at week 20. Moreover, XXK also improved the quality of life of angina patients as measured by the SAQ score and Xueyu Zheng (a type of TCM syndrome) score. We demonstrate that XXK capsule is more effective for attenuating anginal symptoms and improving quality of life in patients with symptomatic chronic stable angina, compared with CDS tablet.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.